Vital Sign MonitoringCOME ON NOWNCT07385092
Continuous Vital Sign Monitoring Versus Routine Spot-checks in Patients After Non-cardiac Surgery
A study testing Unblinded continuous vital sign monitoring and Blinded continuous vital sign monitoring in people with Vital Sign Monitoring and Post Operative Complications, run by Universitätsklinikum Hamburg-Eppendorf at 1 site in Germany.
Trial summary
The "COME ON, NOW!" trial is a randomized, single-center trial in patients recovering from non-cardiac surgery on normal wards investigating whether continuous vital sign monitoring - compared to routine spot-checks by nurses - reduces the total duration of abnormal vital signs per hour during the first 48 hours after… Read more about this study
- Who is it for?
- Ages 45 years and older
- Conditions the study is for
- Vital Sign Monitoring, Post Operative Complications, Non-cardiac Surgery
- What is being tested?
- Unblinded continuous vital sign monitoring and Blinded continuous vital sign monitoring
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 264 participants
- Where
- 1 siteGermany
- Study dates
- 24 Feb 2026to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Consenting patients ≥45 years scheduled for elective non-cardiac (abdominal and thoracic) surgery with planned postoperative admission to a normal ward after an overnight stay in an advanced post-anesthesia care unit.
Who cannot join
- Emergency surgery
- Pregnancy
- Impossibility to perform continuous monitoring with the Radius VSM sensor (Masimo, Irvine, CA)
- Atrial fibrillation
- Patients designated Do Not Resuscitate, or are receiving end-of-life care
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Germany1 site, 1 recruiting
- Recruiting
University Medical Center Hamburg-Eppendorf
Hamburg, Free and Hanseatic City of Hamburg, 20251
Kristen K Thomsen, MD, +4940741070215, kr.thomsen@uke.de
Simon Stemmler, MD, +4940741066077, s.stemmler@uke.de
About this study
Official title: The Effect of Continuous Monitoring Versus Routine Spot-checks on Altered Vital Signs in Patients Recovering From Non-cardiac Surgery on Normal Wards: the "COME ON, NOW!" Trial
The "COME ON, NOW!" trial is a randomized, single-center trial in patients recovering from non-cardiac surgery on normal wards investigating whether continuous vital sign monitoring - compared to routine spot-checks by nurses - reduces the total duration of abnormal vital signs per hour during the first 48 hours after admission to the normal ward.
Read the detailed description
"Surgery went well, and everything is fine. Your relative is still in the operating room, but you can visit her/him this afternoon on the normal ward." Each day, thousands of patient families receive relieving calls like this. A call better reflecting clinical reality would be: "Surgery went well, and everything is fine so far - but the most dangerous time is still ahead. The postoperative period poses a much higher risk for patients than surgery itself." Indeed, rates of major postoperative complications and death remain frighteningly high. If the month after surgery were considered a disease, it would be the third leading cause of death worldwide. Most major complications and deaths occur during the initial hospitalization, under direct medical care.
Postoperative deterioration is usually preceded by changes in vital signs minutes to hours earlier. However, these alterations are frequently missed because vital signs on normal wards are typically assessed only every 4-8 hours. Continuous monitoring may allow earlier detection of instability and enable timely interventions to prevent or mitigate serious complications.
The investgators therefore propose a single-center randomized trial in adults recovering from major non-cardiac surgery on normal wards to compare continuous postoperative vital sign monitoring with routine intermittent spot-checks. Patients will be randomized to blinded or unblinded continuous monitoring using a wearable, wireless sensor system (Radius VSM, Masimo, Irvine, CA). In the unblinded group, clinicians will receive real-time alerts.
The primary outcome will be the cumulative duration of vital sign abnormalities during the first 48 hours on the ward. Secondary outcomes will include clinical interventions triggered by these abnormalities. Exploratorily, the investigators will assess a composite of serious in-hospital complications.
Our long-term goal is to reduce postoperative morbidity and mortality by enabling earlier recognition of clinical deterioration and timely intervention on general wards.
- Conditions
- Vital Sign Monitoring, Post Operative Complications, Non-cardiac Surgery, RCT, Anesthesiology
- Being tested
- Unblinded continuous vital sign monitoring, Blinded continuous vital sign monitoring
- Keywords
- continuous vital signs, vital signs, vital sign monitoring, post-operative care, anesthesiology, anesthesia, hypotension, post-operative complications
- Medical subject headings
- Hypotension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Unblinded continuous vital sign monitoringDevice
Continuous ward monitoring with vital signs available to investigators. Oxygen saturation, blood pressure (intermittent in intervals of 60 minutes), heart rate, and respiratory rate will be continuously measured and streamed to the investigators (specifically, to a central monitor). The investigators will alert nurses or physicians when SpO2 is <85% for ≥2 minutes, respiratory rate is <7/min or >30/min for ≥2 minutes, MAP is <60 mmHg, or heart rate is <45 bpm or >130 bpm for ≥2 minutes, or in case of apnea for ≥1 minute - supplemented by clinical judgement and the complete electronic record. Investigators will alert clinicians when concerning patterns are identified, whether or not alerts have been triggered. Clinicians will determine if response is necessary and what interventions might be appropriate.
Blinded continuous vital sign monitoringDevice
Continuous ward monitoring with vital signs recorded but not available to patients, clinicians, or investigators.
| Study group | Role | What they receive |
|---|---|---|
| Blinded continuous vital sign monitoring | Sham comparator | Continuous ward monitoring with vital signs recorded but not available to patients, clinicians, or investigators. Receives: Device: Blinded continuous vital sign monitoring |
| Unblinded continuous vital sign monitoring | Experimental | Continuous ward monitoring with vital signs available to investigators. Receives: Device: Unblinded continuous vital sign monitoring |
What is being measured
The primary outcome is the main question the study is designed to answer.
Total duration of abnormal vital signs
Total duration of abnormal vital signs per hour (minutes per hour) during the first 48 hours after admission to the normal ward, i.e., the minutes per hour patients have any of the following abnormal vital signs ("any versus none"): peripheral oxygen saturation (SpO2) <85%, mean arterial pressure (MAP) <60 mmHg, heart rate <45 bpm or >130 bpm, and respiratory rate <7/min or >30/min.
Measured: 48 hours after admission to the normal ward
Secondary outcomes (37)
Individual components of the composite primary endpoint
Total duration of a SpO2 <85% per hour (minutes per hour)
Measured: 48 hours after admission to the normal ward
Individual components of the composite primary endpoint
Total duration of a MAP <60 mmHg per hour (minutes per hour)
Measured: 48 hours after admission to the normal ward
Individual components of the composite primary endpoint
Total duration of a heart rate <45 bpm per hour (minutes per hour)
Measured: 48 hours after admission to the normal ward
Individual components of the composite primary endpoint
Total duration of a heart rate >130 bpm per hour (minutes per hour)
Measured: 48 hours after admission to the normal ward
Individual components of the composite primary endpoint
Total duration of a respiratory rate <7/min per hour (minutes per hour)
Measured: 48 hours after admission to the normal ward
Individual components of the composite primary endpoint
Total duration of a respiratory rate >30/min per hour (minutes per hour)
Measured: 48 hours after admission to the normal ward
Quantitative metrics of peripheral oxygen saturation
Area under a SpO2 of 85% (SpO2 <85% x min)
Measured: 48 hours after admission to the normal ward
Quantitative metrics of peripheral oxygen saturation
Time-weighted average hypoxemia (SpO2 <85% x min / total monitoring time)
Measured: 48 hours after admission to the normal ward
Quantitative metrics of peripheral oxygen saturation
Number of SpO2 <85% events per patient
Measured: 48 hours after admission to the normal ward
Quantitative metrics of peripheral oxygen saturation
Proportion of patients with any SpO2 <85% event
Measured: 48 hours after admission to the normal ward
Quantitative metrics of peripheral oxygen saturation
Total cumulative duration of SpO2 <85%
Measured: 48 hours after admission to the normal ward
Quantitative metrics of mean arterial pressure
Area under a MAP of 60 mmHg (mmHg x min)
Measured: 48 hours after admission to the normal ward
Quantitative metrics of mean arterial pressure
Time-weighted average hypotension (MAP <60 mmHg x min / total monitoring time)
Measured: 48 hours after admission to the normal ward
Quantitative metrics of mean arterial pressure
Number of MAP <60 mmHg events per patient
Measured: 48 hours after admission to the normal ward
Quantitative metrics of mean arterial pressure
Proportion of patients with any MAP <60 mmHg event
Measured: 48 hours after admission to the normal ward
Quantitative metrics of mean arterial pressure
Total cumulative duration of MAP <60 mmHg
Measured: 48 hours after admission to the normal ward
Quantitative metrics of heart rate
Area under a heart rate of 45 bpm (<45 bpm x min)
Measured: 48 hours after admission to the normal ward
Quantitative metrics of heart rate
Area above a heart rate of 130 bpm (>130 bpm x min)
Measured: 48 hours after admission to the normal ward
Quantitative metrics of heart rate
Time-weighted average bradycardia (<45 bpm x min / total monitoring time)
Measured: 48 hours after admission to the normal ward
Quantitative metrics of heart rate
Time-weighted average tachycardia (>130 bpm x min / total monitoring time)
Measured: 48 hours after admission to the normal ward
Quantitative metrics of heart rate
Number of events per patient with heart rate <45 bpm
Measured: 48 hours after admission to the normal ward
Quantitative metrics of heart rate
Number of events per patient with heart rate >130 bpm
Measured: 48 hours after admission to the normal ward
Quantitative metrics of heart rate
Proportion of patients with any event with heart rate <45 bpm
Measured: 48 hours after admission to the normal ward
Quantitative metrics of heart rate
Proportion of patients with any event with heart rate >130 bpm
Measured: 48 hours after admission to the normal ward
Quantitative metrics of heart rate
Total cumulative duration of heart rate <45 bpm
Measured: 48 hours after admission to the normal ward
Quantitative metrics of heart rate
Total cumulative duration of heart rate >130 bpm
Measured: 48 hours after admission to the normal ward
Quantitative metrics of respiratory rate
Area under a respiratory rate 7/min (<7/min x min)
Measured: 48 hours after admission to the normal ward
Quantitative metrics of respiratory rate
Area above a respiratory rate 30/min (>30/min x min)
Measured: 48 hours after admission to the normal ward
Quantitative metrics of respiratory rate
Time-weighted average bradypnea (<7/min x min / total monitoring time)
Measured: 48 hours after admission to the normal ward
Quantitative metrics of respiratory rate
Time-weighted average tachypnea (>30/min x min / total monitoring time)
Measured: 48 hours after admission to the normal ward
Quantitative metrics of respiratory rate
Number of events per patient with respiratory rate <7/min
Measured: 48 hours after admission to the normal ward
Quantitative metrics of respiratory rate
Number of events per patient with respiratory rate >30/min
Measured: 48 hours after admission to the normal ward
Quantitative metrics of respiratory rate
Proportion of patients with any event with respiratory rate <7/min
Measured: 48 hours after admission to the normal ward
Quantitative metrics of respiratory rate
Proportion of patients with any event with respiratory rate >30/min
Measured: 48 hours after admission to the normal ward
Quantitative metrics of respiratory rate
Total cumulative duration of respiratory rate <7/min
Measured: 48 hours after admission to the normal ward
Quantitative metrics of respiratory rate
Total cumulative duration of respiratory rate >30/min
Measured: 48 hours after admission to the normal ward
The incidence of a composite of clinical interventions for desaturation, hypoventilation, tachypnea, tachycardia, bradycardia, and hypotension.
Clinical responses will be considered interventions if:
- they are documented in the medical record, and
- meet at least one of the following criteria:
- Respiratory treatment if preceded within 2 hours by SpO2 <85% or respiratory rate <7/min and investigator alert: oxygen, inhaled bronchodilators, naloxone, diuretics, and ventilatory support.
- Tachycardia interventions preceded within 2 hours by a heart rate of >130 bpm and investigator alert, excluding chronically used preoperative medications: beta-blockers, calcium channel blockers, amiodarone, adenosine, and cardioversion.
- Bradycardia interventions preceded within 2 hours by a heart rate <45 bpm and investigator alert: Isoproterenol, atropine, glycopyrrolate, epinephrine, cardiac pacing, cardioversion.
- Hypotension interventions preceded within 2 hours by a mean arterial pressure <60 mmHg and investigator alerts: crystalloids, colloids, norepinephrine, albumin.
- Any activation of the rapid response team or ICU transfer.
Measured: 48 hours after admission to the normal ward
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Feb 2026
- Study start24 Feb 2026
- Primary completion1 Nov 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Vital Sign MonitoringStudies of the same condition, open and under way.
- More trials run by Universitätsklinikum Hamburg-EppendorfThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 264 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Kristen Thomsen, Universitätsklinikum Hamburg-Eppendorf
- Investigators
- Bernd Saugel, MD, Principal investigator, Universitätsklinikum Hamburg-Eppendorf
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07385092
- Sponsor's protocol ID
- 2023-101178-BO-ff
- Other IDs
- 2023
- Acronym
- COME ON NOW
- Status last verified
- Feb 2026
- First submitted
- 13 Jan 2026
- Last updated
- 2 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Continuous Monitoring Versus Routine Spot-checks on Altered Vital Signs in Patients Recovering From Non-cardiac Surgery on Normal Wards: the "COME ON, NOW!" Trial
- ClinicalTrials.gov ID
- NCT07385092
- Acronym / sponsor ID
- COME ON NOW / 2023-101178-BO-ff
- Conditions
- Vital Sign Monitoring, Post Operative Complications, Non-cardiac Surgery, RCT, Anesthesiology
- Keywords
- continuous vital signs, vital signs, vital sign monitoring, post-operative care, anesthesiology, anesthesia, hypotension, post-operative complications
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 264 participants (estimated)
- Lead sponsor
- Universitätsklinikum Hamburg-EppendorfUniversity, hospital or other
- Study start
- 24 Feb 2026 (actual)
- Primary completion
- 1 Nov 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 3 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The "COME ON, NOW!" trial is a randomized, single-center trial in patients recovering from non-cardiac surgery on normal wards investigating whether continuous vital sign monitoring - compared to routine spot-checks by nurses - reduces the total duration of abnormal vital signs per hour during the first 48 hours after admission to the normal ward.
Detailed description
"Surgery went well, and everything is fine. Your relative is still in the operating room, but you can visit her/him this afternoon on the normal ward." Each day, thousands of patient families receive relieving calls like this. A call better reflecting clinical reality would be: "Surgery went well, and everything is fine so far - but the most dangerous time is still ahead. The postoperative period poses a much higher risk for patients than surgery itself." Indeed, rates of major postoperative complications and death remain frighteningly high. If the month after surgery were considered a disease, it would be the third leading cause of death worldwide. Most major complications and deaths occur during the initial hospitalization, under direct medical care.
Postoperative deterioration is usually preceded by changes in vital signs minutes to hours earlier. However, these alterations are frequently missed because vital signs on normal wards are typically assessed only every 4-8 hours. Continuous monitoring may allow earlier detection of instability and enable timely interventions to prevent or mitigate serious complications.
The investgators therefore propose a single-center randomized trial in adults recovering from major non-cardiac surgery on normal wards to compare continuous postoperative vital sign monitoring with routine intermittent spot-checks. Patients will be randomized to blinded or unblinded continuous monitoring using a wearable, wireless sensor system (Radius VSM, Masimo, Irvine, CA). In the unblinded group, clinicians will receive real-time alerts.
The primary outcome will be the cumulative duration of vital sign abnormalities during the first 48 hours on the ward. Secondary outcomes will include clinical interventions triggered by these abnormalities. Exploratorily, the investigators will assess a composite of serious in-hospital complications.
Our long-term goal is to reduce postoperative morbidity and mortality by enabling earlier recognition of clinical deterioration and timely intervention on general wards.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Blinded continuous vital sign monitoring | Sham comparator | Device: Blinded continuous vital sign monitoringContinuous ward monitoring with vital signs recorded but not available to patients, clinicians, or investigators. |
| Unblinded continuous vital sign monitoring | Experimental | Device: Unblinded continuous vital sign monitoringContinuous ward monitoring with vital signs available to investigators. |
Who may qualify
- Ages
- 45 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Consenting patients ≥45 years scheduled for elective non-cardiac (abdominal and thoracic) surgery with planned postoperative admission to a normal ward after an overnight stay in an advanced post-anesthesia care unit.
Key exclusion criteria (5 listed)
- Emergency surgery
- Pregnancy
- Impossibility to perform continuous monitoring with the Radius VSM sensor (Masimo, Irvine, CA)
- Atrial fibrillation
- Patients designated Do Not Resuscitate, or are receiving end-of-life care
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Unblinded continuous vital sign monitoringContinuous ward monitoring with vital signs available to investigators. Oxygen saturation, blood pressure (intermittent in intervals of 60 minutes), heart rate, and respiratory rate will be continuously measured and streamed to the investigators (specifically, to a central monitor). The investigators will alert nurses or physicians when SpO2 is <85% for ≥2 minutes, respiratory rate is <7/min or >30/min for ≥2 minutes, MAP is <60 mmHg, or heart rate is <45 bpm or >130 bpm for ≥2 minutes, or in case of apnea for ≥1 minute - supplemented by clinical judgement and the complete electronic record. Investigators will alert clinicians when concerning patterns are identified, whether or not alerts have been triggered. Clinicians will determine if response is necessary and what interventions might be appropriate. | Device | Unblinded continuous vital sign monitoring |
| Blinded continuous vital sign monitoringContinuous ward monitoring with vital signs recorded but not available to patients, clinicians, or investigators. | Device | Blinded continuous vital sign monitoring |
Primary outcome
Total duration of abnormal vital signs
Time frame: 48 hours after admission to the normal ward
Total duration of abnormal vital signs per hour (minutes per hour) during the first 48 hours after admission to the normal ward, i.e., the minutes per hour patients have any of the following abnormal vital signs ("any versus none"): peripheral oxygen saturation (SpO2) <85%, mean arterial pressure (MAP) <60 mmHg, heart rate <45 bpm or >130 bpm, and respiratory rate <7/min or >30/min.
37 secondary outcomes
Individual components of the composite primary endpoint
Time frame: 48 hours after admission to the normal ward
Individual components of the composite primary endpoint
Time frame: 48 hours after admission to the normal ward
Individual components of the composite primary endpoint
Time frame: 48 hours after admission to the normal ward
Individual components of the composite primary endpoint
Time frame: 48 hours after admission to the normal ward
Individual components of the composite primary endpoint
Time frame: 48 hours after admission to the normal ward
Individual components of the composite primary endpoint
Time frame: 48 hours after admission to the normal ward
Quantitative metrics of peripheral oxygen saturation
Time frame: 48 hours after admission to the normal ward
Quantitative metrics of peripheral oxygen saturation
Time frame: 48 hours after admission to the normal ward
Quantitative metrics of peripheral oxygen saturation
Time frame: 48 hours after admission to the normal ward
Quantitative metrics of peripheral oxygen saturation
Time frame: 48 hours after admission to the normal ward
Quantitative metrics of peripheral oxygen saturation
Time frame: 48 hours after admission to the normal ward
Quantitative metrics of mean arterial pressure
Time frame: 48 hours after admission to the normal ward
Quantitative metrics of mean arterial pressure
Time frame: 48 hours after admission to the normal ward
Quantitative metrics of mean arterial pressure
Time frame: 48 hours after admission to the normal ward
Quantitative metrics of mean arterial pressure
Time frame: 48 hours after admission to the normal ward
Quantitative metrics of mean arterial pressure
Time frame: 48 hours after admission to the normal ward
Quantitative metrics of heart rate
Time frame: 48 hours after admission to the normal ward
Quantitative metrics of heart rate
Time frame: 48 hours after admission to the normal ward
Quantitative metrics of heart rate
Time frame: 48 hours after admission to the normal ward
Quantitative metrics of heart rate
Time frame: 48 hours after admission to the normal ward
Quantitative metrics of heart rate
Time frame: 48 hours after admission to the normal ward
Quantitative metrics of heart rate
Time frame: 48 hours after admission to the normal ward
Quantitative metrics of heart rate
Time frame: 48 hours after admission to the normal ward
Quantitative metrics of heart rate
Time frame: 48 hours after admission to the normal ward
Quantitative metrics of heart rate
Time frame: 48 hours after admission to the normal ward
Quantitative metrics of heart rate
Time frame: 48 hours after admission to the normal ward
Quantitative metrics of respiratory rate
Time frame: 48 hours after admission to the normal ward
Quantitative metrics of respiratory rate
Time frame: 48 hours after admission to the normal ward
Quantitative metrics of respiratory rate
Time frame: 48 hours after admission to the normal ward
Quantitative metrics of respiratory rate
Time frame: 48 hours after admission to the normal ward
Quantitative metrics of respiratory rate
Time frame: 48 hours after admission to the normal ward
Quantitative metrics of respiratory rate
Time frame: 48 hours after admission to the normal ward
Quantitative metrics of respiratory rate
Time frame: 48 hours after admission to the normal ward
Quantitative metrics of respiratory rate
Time frame: 48 hours after admission to the normal ward
Quantitative metrics of respiratory rate
Time frame: 48 hours after admission to the normal ward
Quantitative metrics of respiratory rate
Time frame: 48 hours after admission to the normal ward
The incidence of a composite of clinical interventions for desaturation, hypoventilation, tachypnea, tachycardia, bradycardia, and hypotension.
Time frame: 48 hours after admission to the normal ward
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Vital Sign Monitoring
Recruiting
Hospital Based Continuous Patient Monitoring System
Trauma, Appendectomy
Not yet recruitingObservational study
ADVANCE-FORSEE. ADVANCEd Video Monitoring FOR Early Signaling of Adverse Events and Optimal dischargE Planning.
Vital Signs Monitoring, Complication
RecruitingObservational study
Vision Baby : The Measurement of Vital Signs in Neonates by Lifelight® Software in Comparison to the Standard of Care
Neonatal Diseases and Abnormalities, Vital Sign Monitoring
Recruiting
The Effect of Diaphragmatic Breathing Exercises Before Gastroscopy on Anxiety, Fear, and Vital Signs
Breath Exercise, State Anxiety
Recruiting
Continuous Versus Intermittent Ward Monitoring
Surgery
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Bernd Saugel, MD principal investigator
Universitätsklinikum Hamburg-Eppendorf
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Unblinded continuous vital sign monitoring and Blinded continuous vital sign monitoring in people with Vital Sign Monitoring and Post Operative Complications, run by Universitätsklinikum Hamburg-Eppendorf at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Kristen K Thomsen, MD (+4940741070215, kr.thomsen@uke.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Total duration of abnormal vital signs (time frame: 48 hours after admission to the normal ward). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Mar 2026.